AMR: The Growing Global Crisis

The global fight against antimicrobial resistance (AMR) is being outpaced by the very infections it seeks to combat. Superbugs kill over a million people each year, and that number is expected to skyrocket by 2050. A new report from the Access to Medicine Foundation highlights a major problem: drug companies aren't developing enough new antibiotics. The system designed to encourage this research is failing.

Why Drugmakers Are Cutting Back on Antibiotics

Big drug companies are cutting antibiotic research by 35%, moving instead to more profitable areas like cancer drugs. This leaves a gap in developing new treatments. Small and medium-sized companies (SMEs) are now doing much of the work, handling nearly a quarter of drug projects. But these smaller firms often lack the money and reach to succeed, struggling to get their discoveries to market. Even companies like GSK, Otsuka, and Shionogi, which continue to invest, can't fill the void left by others.

Company Valuations Show Divergent Focus

The financial performance and investor expectations for some drugmakers involved in antibiotic research offer insight. GSK, developing the antibiotic gepotidacin, has a Price-to-Earnings (P/E) ratio between 14.7x and 15.2x. Otsuka Holdings trades at a P/E of 19.9x to 26.3x, suggesting investors expect moderate growth. Shionogi's P/E is around 14.1x to 19.3x. Aurobindo Pharma's P/E ranges from 19.0x to 20.4x. Hikma Pharmaceuticals has a lower P/E of 7.4x to 12.5x, possibly reflecting its focus on generics and specialized drugs. Sandoz shows varied P/E figures, from 38.2x upwards, depending on the reporting period. Teva Pharmaceutical Industries, a major generics producer, has a P/E around 25.1x to 26.2x. Higher P/E ratios generally suggest investors are looking for significant future growth, which can be more readily found in other areas than antibiotic development.

Barriers to New Antibiotics: Policy, Access, and Kids

The main problem isn't just company strategy, but widespread market issues and slow government action. Developing antibiotics is risky, with many failures and low profits compared to drugs for chronic illnesses. This makes it a poor investment for typical companies. Governments need to step in with 'push' incentives (like grants to lower R&D costs) and 'pull' incentives (like guaranteed payments for successful drugs). But these programs are often too slow or too small. Access to needed antibiotics is also poor in poorer countries. Children, who are hit hard by AMR, face long delays for suitable medicines, as it can take ten years longer to get pediatric versions approved.

Why the Antibiotic Pipeline Is So Fragile

The system for developing new antibiotics is fragile. Only 4 large drug companies are actively researching new antibiotics, out of 42 in total development, which makes the pipeline very risky. Some analysts are cautious about companies like GSK, with some rating them as 'Reduce'. Relying on smaller companies (SMEs) is difficult because they often lack funding and face scientific challenges. While acquisitions by companies like Pfizer and Shionogi help promising drugs, they don't fix the core problem of underfunding early research. The current market model is so broken that even a successful drug launch can lead a company to bankruptcy, as happened with SME Achaogen. Without major market changes and strong government action, future access to essential antibiotics is uncertain, particularly for those who need them most.

The Path Forward: Urgent Action Needed

To move forward, we need new ways to finance drug development and strong partnerships between governments and the private sector. Governments and policymakers must quickly create market incentives that make antibiotic research a sustainable investment. They also need to ensure everyone can access these vital medicines. If we don't fundamentally change how antibiotic innovation is funded and valued, the growing AMR crisis will overwhelm the drug industry's ability to keep up.